KOSDAQ - Delayed Quote KRW

302440.KQ,0P0001LXML,68832 (302440.KQ)

55,000.00

-700.00

(-1.26%)

At close: July 20 at 5:00:00 AM GMT+9

SK bioscience Joins Korea's National Initiative to Develop Avian Influenza Vaccine Amid Rising Pandemic Threats

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that it has been selected for the Korea Disease Control and Prevention Agency (KDCA)'s Priority Infectious Disease Pandemic Preparedness Rapid R&D Support Program.

PR Newswire 10 days ago

302440.KQ
-1.26%

302440.KS
SK bioscience Expands Influenza Vaccine Exports to Southern Hemisphere Market

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that the company has begun shipping its self-developed influenza vaccine, SKYCellflu, from its vaccine manufacturing facility L HOUSE to Southern Hemisphere markets, including Southeast Asia and Latin America. A total of 750,000 doses will be supplied in the first half of the year.

PR Newswire 2 months ago

302440.KQ
-1.26%

302440.KS
SK bioscience Initiates Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced the commencement of global Phase 1/2 clinical trials for its mRNA-based Japanese encephalitis vaccine candidate, GBP560.

PR Newswire 2 months ago

302440.KQ
-1.26%

302440.KS
SK bioscience Receives Approval for Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced today that it has received approval from the Human Research Ethics Committee (HREC) in Australia for the clinical trial protocols of a Phase 1/2 trials for its mRNA-based Japanese encephalitis vaccine candidate, GBP560.

PR Newswire 5 months ago

302440.KQ
-1.26%

302440.KS
SK bioscience Announces Approval of Its Quadrivalent Influenza Vaccine in Indonesia

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that Indonesia's Food and Drug Agency, BPOM (Badan Pengawas Obat dan Makanan), has approved the Biologics License Application (BLA) for the SKYCellflu Quadrivalent prefilled syringe, the world's first quadrivalent cell-cultured influenza vaccine. This is the first time a domestically made influenza vaccine has received approval in Indonesia.

PR Newswire 6 months ago

302440.KQ
-1.26%

302440.KS
Korea's SK bioscience Acquires Stake in U.S. Biotech Fina Biosolutions

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced today that the company has signed an agreement to acquire a stake in Fina Biosolutions (FinaBio), a promising R&D biotechnology company based in Rockville, Maryland, United States, by investing USD 3 million. With this acquisition, SK bioscience will become FinaBio's first and sole strategic investor.

PR Newswire 7 months ago

302440.KQ
-1.26%

302440.KS
South Korea's SK bioscience Completes Acquisition of Germany's CDMO IDT Biologika

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced the successful completion of its acquisition of a controlling stake in a German company, IDT Biologika, one of the top 10 global vaccine contract development manufacturing organizations (CDMO).

PR Newswire 7 months ago

302440.KQ
-1.26%

302440.KS

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

302440.KQ,0P0001LXML,68832 (302440.KQ)

SK bioscience Joins Korea's National Initiative to Develop Avian Influenza Vaccine Amid Rising Pandemic Threats

SK bioscience Expands Influenza Vaccine Exports to Southern Hemisphere Market

SK bioscience Initiates Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate

SK bioscience Receives Approval for Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate

SK bioscience Announces Approval of Its Quadrivalent Influenza Vaccine in Indonesia

Korea's SK bioscience Acquires Stake in U.S. Biotech Fina Biosolutions

South Korea's SK bioscience Completes Acquisition of Germany's CDMO IDT Biologika